Catalog Number: 11972308160
Immunoassay for the in vitro quantitative determination of degradation products of type I collagen in human serum and plasma as an aid in assessing bone resorption. The test may be used as an aid in monitoring antiresorptive therapies (e.g. bisphosphonates, hormone replacement therapy - HRT) in postmenopausal women and individuals diagnosed with osteopenia.
Store at 2-8 °C.
Traceability: This method has been standardized against reference standards precisely defined by weighing out synthetic peptide.
0.010-6.00 ng/mL or 10-6000 pg/mL (defined by the lower detection limit and the maximum of the master curve). Values below the lower detection limit are reported as < 0.010 ng/mL (< 10 pg/mL). Values above the measuring range are reported as > 6.00 ng/mL (> 6000 pg/mL).
Lower detection limit of the test
Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.
Precision was determined using Elecsys reagents, pooled human sera and controls in a protocol
A comparison of the Elecsys β-CrossLaps/serum assay (y) - ng/mL - with the Serum CrossLaps™ One Step ELISA test from Osteometer (x) - pmol/L - using human serum is shown in the diagram below (linear regression):
The monoclonal antibodies used in the Elecsys β-CrossLaps/serum assay recognize all fragments of type I collagen containing the β-8AA octapeptide twice. No cross-reactivity detectable with osteocalcin, PTH or bone ALP.